{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:57:30Z","timestamp":1762077450517,"version":"build-2065373602"},"reference-count":55,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMP"],"abstract":"<jats:p>Metastatic breast cancer (MBC) remains in most cases an incurable disease with genetic complexity and heterogeneity. Improvements in classification and management have been introduced, in addition to the development of endocrine and anti-HER2 targeted therapies. Currently, efforts are being made to delineate the best approach for the genomic landscape of MBC and, as result, molecular therapeutic targets. Here, we highlight the recent developments in the cytopathology of MBC, discussing cytological diagnostic approaches in the characterization of hallmarks, such as immunocytochemistry and genomic biomarkers. Cytological material can be processed for ancillary testing for diagnostic and therapeutic purposes. Reassessment of receptor status is indicated due to changes in tumor biology and metastatic presentation. PD-L1 expression is the only approved biomarker for predicting immune checkpoint inhibitor response in metastatic TNBC, evaluated by immunostaining. The feasibility of applying PD-L1 assays in MBC cytological samples can be recommended, with the adoption of a combined positive score. Non-formalin cytological samples provide higher purity, cellular yield, and better tumor fraction for single-multi gene assays. In MBC, molecular tests enable personalized therapy such as PIK3CA, NTRK fusion genes, and MSI. Cytopathology combined with molecular analysis must be performed effectively in routine clinical practice, through procedure standardization and experience dissemination.<\/jats:p>","DOI":"10.3390\/jmp3040028","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T03:48:12Z","timestamp":1669175292000},"page":"329-338","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Optimal Assessment of Metastatic Breast Carcinoma: The Value of Cytopathology Combined with Molecular Analysis"],"prefix":"10.3390","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3860-6660","authenticated-orcid":false,"given":"Ricella","family":"Souza da Silva","sequence":"first","affiliation":[{"name":"IPATIMUP Diagnostics, IPATIMUP\u2014Institute of Molecular Pathology and Immunology of Porto University, 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1006-6946","authenticated-orcid":false,"given":"Fernando","family":"Schmitt","sequence":"additional","affiliation":[{"name":"IPATIMUP Diagnostics, IPATIMUP\u2014Institute of Molecular Pathology and Immunology of Porto University, 4200-135 Porto, Portugal"},{"name":"Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"},{"name":"CINTESIS@RISE (Health Research Network), 4200-450 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer Statistics","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"3","article-title":"Introduction to This Special Issue \u201cBreast Cancer Metastasis","volume":"6","author":"Schiemann","year":"2020","journal-title":"J. Cancer Metastasis Treat."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast Cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/cyt.12158","article-title":"Metastatic Breast Cancer: Mechanisms and Opportunities for Cytology","volume":"25","author":"Martins","year":"2014","journal-title":"Cytopathol. Off. J. Br. Soc. Clin. Cytol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the Diagnosis, Staging and Treatment of Patients with Metastatic Breast Cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00428-018-2390-5","article-title":"Comparative Clinicopathological and Cytomorphological Analyses of Peritoneal Carcinomatosis Associated with Metastatic Breast Carcinoma and Primary Peritoneal\/Ovarian Carcinoma in Patients with a History of Breast Carcinoma","volume":"473","author":"Na","year":"2018","journal-title":"Virchows Arch. Int. J. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00432-017-2428-0","article-title":"Improved Systemic Treatment for Early Breast Cancer Improves Cure Rates, Modifies Metastatic Pattern and Shortens Post-Metastatic Survival: 35-Year Results from the Munich Cancer Registry","volume":"143","author":"Eckel","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3816\/CBC.2000.n.021","article-title":"Cytopathology of Metastatic Breast Cancer","volume":"1","author":"Cramer","year":"2000","journal-title":"Clin. Breast Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000522542","article-title":"Immunohistochemistry Applied to Breast Cytological Material","volume":"89","author":"Pinto","year":"2022","journal-title":"Pathobiology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"933","DOI":"10.5858\/arpa.2020-0119-CP","article-title":"Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies: Guideline From the College of American Pathologists in Collaboration With the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology, Society of Interventional Radiology, and Society of Thoracic Radiology","volume":"144","author":"Dacic","year":"2020","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1200\/JCO.2015.61.1459","article-title":"Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"33","author":"Somerfield","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","article-title":"Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Gradishar","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000488382","article-title":"Evaluation of the HER2 and Hormone Receptor Status in Metastatic Breast Cancer Using Cell Blocks: A Multi-Institutional Study","volume":"62","author":"Nishimura","year":"2018","journal-title":"Acta Cytol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/cyt.12993","article-title":"Immunocytochemistry for Diagnostic Cytopathology-A Practical Guide","volume":"32","author":"Kanber","year":"2021","journal-title":"Cytopathol. Off. J. Br. Soc. Clin. Cytol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/dc.21841","article-title":"Assessment of Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) Status in the Fine Needle Aspirates of Metastatic Breast Carcinomas","volume":"41","author":"Monaco","year":"2013","journal-title":"Diagn. Cytopathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"vdab010","DOI":"10.1093\/noajnl\/vdab010","article-title":"Systematic Review and Meta-Analysis of Breast Cancer Brain Metastasis and Primary Tumor Receptor Expression Discordance","volume":"3","author":"Kotecha","year":"2021","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10555-016-9631-3","article-title":"Estrogen, Progesterone, and HER2\/Neu Receptor Discordance between Primary and Metastatic Breast Tumours-a Review","volume":"35","author":"Yeung","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10549-017-4529-5","article-title":"Differential Presentation and Survival of de Novo and Recurrent Metastatic Breast Cancer over Time: 1990\u20132010","volume":"167","author":"Malmgren","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2010.33.5232","article-title":"Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients with Breast Cancer","volume":"30","author":"Amir","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejca.2013.10.004","article-title":"A Meta-Analysis of Oestrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Discordance between Primary Breast Cancer and Metastases","volume":"50","author":"Aurilio","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s12282-015-0615-x","article-title":"Benefits of Using the Cell Block Method to Determine the Discordance of the HR\/HER2 Expression in Patients with Metastatic Breast Cancer","volume":"23","author":"Nakayama","year":"2016","journal-title":"Breast Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jasc.2016.10.001","article-title":"Cytologic Assessment of Estrogen Receptor, Progesterone Receptor, and HER2 Status in Metastatic Breast Carcinoma","volume":"6","author":"Pareja","year":"2017","journal-title":"J. Am. Soc. Cytopathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/jnci\/djx273","article-title":"Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-Analysis","volume":"110","author":"Schrijver","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.18632\/oncotarget.27163","article-title":"Clinical Significance of Evaluating Hormone Receptor and HER2 Protein Using Cell Block against Metastatic Breast Cancer: A Multi-Institutional Study","volume":"10","author":"Matsui","year":"2019","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/neuonc\/noaa025","article-title":"Estrogen\/Progesterone Receptor and HER2 Discordance between Primary Tumor and Brain Metastases in Breast Cancer and Its Effect on Treatment and Survival","volume":"22","author":"Sperduto","year":"2020","journal-title":"Neuro-Oncology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/dc.21389","article-title":"Reliability of Her2\/Neu, Estrogen Receptor, and Progesterone Receptor Testing by Immunohistochemistry on Cell Block of FNA and Serous Effusions from Patients with Primary and Metastatic Breast Carcinoma","volume":"39","author":"Shabaik","year":"2011","journal-title":"Diagn. Cytopathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2303.2011.00853.x","article-title":"Immunochemistry for Oestrogen Receptor, Progesterone Receptor and HER2 on Cell Blocks in Primary Breast Carcinoma","volume":"23","author":"Kumar","year":"2012","journal-title":"Cytopathol. Off. J. Br. Soc. Clin. Cytol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-2303.2011.00934.x","article-title":"Fine Needle Aspirate Cell Blocks Are Reliable for Detection of Hormone Receptors and HER-2 by Immunohistochemistry in Breast Carcinoma","volume":"24","author":"Viero","year":"2013","journal-title":"Cytopathol. Off. J. Br. Soc. Clin. Cytol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/dc.22897","article-title":"ER, PR, and Her2 Immunocytochemistry on Cell-Transferred Cytologic Smears of Primary and Metastatic Breast Carcinomas: A Comparison Study with Formalin-Fixed Cell Blocks and Surgical Biopsies","volume":"41","author":"Ferguson","year":"2013","journal-title":"Diagn. Cytopathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4103\/JOC.JOC_117_18","article-title":"Hormone Receptors and Human Epidermal Growth Factor (HER2) Expression in Fine-Needle Aspirates from Metastatic Breast Carcinoma\u2014Role in Patient Management","volume":"36","author":"Francis","year":"2019","journal-title":"J. Cytol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000499697","article-title":"Ancillary Tests in Breast Cytology: A Practical Guide","volume":"63","author":"Beca","year":"2019","journal-title":"Acta Cytol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Verret, B., Bottosso, M., Hervais, S., and Pistilli, B. (2022). The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer: The Contribution of Molecular Profiling. Cancers, 14.","DOI":"10.3390\/cancers14174203"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/cyt.12982","article-title":"PD-L1 and beyond: Immuno-Oncology in Cytopathology","volume":"32","author":"Iaccarino","year":"2021","journal-title":"Cytopathol. Off. J. Br. Soc. Clin. Cytol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/dc.24955","article-title":"Program Death Ligand-1 Immunocytochemistry in Lung Cancer Cytological Samples: A Systematic Review","volume":"50","author":"Satturwar","year":"2022","journal-title":"Diagn. Cytopathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1159\/000517078","article-title":"PD-L1 Testing in Cytological Non-Small Cell Lung Cancer Specimens: A Comparison with Biopsies and Review of the Literature","volume":"65","author":"Mansour","year":"2021","journal-title":"Acta Cytol."},{"key":"ref_36","unstructured":"Zhang, X. (2022). Molecular Classification of Breast Cancer. Arch. Pathol. Lab. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the Use of Next-Generation Sequencing (NGS) for Patients with Metastatic Cancers: A Report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/1878-0261.12776","article-title":"Fine-Needle Aspiration as an Alternative to Core Needle Biopsy for Tumour Molecular Profiling in Precision Oncology: Prospective Comparative Study of next-Generation Sequencing in Cancer Patients Included in the SHIVA02 Trial","volume":"15","author":"Dupain","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/cyt.12972","article-title":"A Decade of Change: Trends in the Practice of Cytopathology at a Tertiary Care Cancer Centre","volume":"32","author":"Dinarvand","year":"2021","journal-title":"Cytopathology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/cncy.21599","article-title":"The Use of FNA Samples for Whole-Exome Sequencing and Detection of Somatic Mutations in Breast Cancer Surgical Specimens","volume":"123","author":"Lee","year":"2015","journal-title":"Cancer Cytopathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/modpathol.2016.228","article-title":"Concurrent Fine Needle Aspirations and Core Needle Biopsies: A Comparative Study of Substrates for next-Generation Sequencing in Solid Organ Malignancies","volume":"30","author":"Chen","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/cyt.12974","article-title":"Next Generation Sequencing in Cytology","volume":"32","author":"Pisapia","year":"2021","journal-title":"Cytopathol. Off. J. Br. Soc. Clin. Cytol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"983102","DOI":"10.3389\/fmolb.2022.983102","article-title":"Tissue Management in Precision Medicine: What the Pathologist Needs to Know in the Molecular Era","volume":"9","author":"Pinto","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00428-022-03343-2","article-title":"Expert Opinion on NSCLC Small Specimen Biomarker Testing\u2014Part 1: Tissue Collection and Management","volume":"481","author":"Kerr","year":"2022","journal-title":"Virchows Arch."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cncy.22126","article-title":"Comparison of Cytocentrifugation Supernatant Fluid and Formalin-Fixed Paraffin-Embedded Tissue for Targeted next-Generation Sequencing","volume":"127","author":"Janaki","year":"2019","journal-title":"Cancer Cytopathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jasc.2022.02.004","article-title":"Molecular Yield and Cytomorphologic Assessment of Fine Needle Aspiration Specimen Supernatants","volume":"11","author":"Ruff","year":"2022","journal-title":"J. Am. Soc. Cytopathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/cncy.22400","article-title":"Tumor Mutational Burden on Cytological Samples: A Pilot Study","volume":"129","author":"Pepe","year":"2021","journal-title":"Cancer Cytopathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/jclinpath-2017-204561","article-title":"How to Prepare Cytological Samples for Molecular Testing","volume":"70","author":"Bellevicine","year":"2017","journal-title":"J. Clin. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/cac2.12358","article-title":"Breast Cancer: An up-to-Date Review and Future Perspectives","volume":"42","author":"Hong","year":"2022","journal-title":"Cancer Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","article-title":"Genomic Characterization of Metastatic Breast Cancers","volume":"569","author":"Bertucci","year":"2019","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.22.01063","article-title":"Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update","volume":"40","author":"Henry","year":"2022","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100040","DOI":"10.1016\/j.esmoop.2020.100040","article-title":"Druggable Targets Meet Oncogenic Drivers: Opportunities and Limitations of Target-Based Classification of Tumors and the Role of Molecular Tumor Boards","volume":"6","author":"Danesi","year":"2021","journal-title":"ESMO Open"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1158\/1078-0432.CCR-21-2600","article-title":"U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review","volume":"28","author":"Arora","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Schmitt, F., and Lozano, M.D. (2022). Molecular\/Biomarker Testing in Lung Cytology: A Practical Approach. Diagn. Cytopathol.","DOI":"10.1002\/dc.25054"},{"key":"ref_55","first-page":"362","article-title":"The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"}],"container-title":["Journal of Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2673-5261\/3\/4\/28\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:24:31Z","timestamp":1760145871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2673-5261\/3\/4\/28"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["jmp3040028"],"URL":"https:\/\/doi.org\/10.3390\/jmp3040028","relation":{},"ISSN":["2673-5261"],"issn-type":[{"type":"electronic","value":"2673-5261"}],"subject":[],"published":{"date-parts":[[2022,11,22]]}}}